Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00187096 · ClinicalTrials.gov registry record · NA
Natural Killer (NK) Cell Transplantation for AML
A NA study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT00187096 is a NA study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 49 participants.
The verdict
NCT00187096, a NA study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of infusing natural killer cells from a donor as treatment for patients with acute myeloid leukemia in remission or who have experienced relapse.
Interventions
- DRUG Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2
- PROCEDURE Natural Killer Cell Infusion
- DEVICE CliniMACS System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2005-09 |
| Est. Completion | 2013-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00187096
The ClinicalTrials.gov registry entry for NCT00187096 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2 is the first listed.
NCT00187096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00187096 about?
NCT00187096 is a clinical study titled "Natural Killer (NK) Cell Transplantation for AML". The purpose of this study is to assess the safety and efficacy of infusing natural killer cells from a donor as treatment for patients with acute myeloid leukemia in remission or who have experienced relapse.
What is the current status of trial NCT00187096?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2005-09. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00187096?
The interventions under investigation include: Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2 (DRUG), Natural Killer Cell Infusion (PROCEDURE), CliniMACS System (DEVICE).
Who is sponsoring clinical trial NCT00187096?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.